PDCD1 and melanoma: Various MAPK and tyrosine kinases pathways that are major oncogenic pathways involved in melanoma tumorigenesis were significantly downregulated in tumors treated with the combination of SAM+anti-PD-1 but not in SAM (except one of the MAPK pathways) and anti-PD-1 alone (Table 1) (41, 42).